Journal
Journal for Immunotherapy of Cancer
Publication Date
8-1-2021
Volume
9
Issue
8
First Page
e002757
Document Type
Open Access Publication
DOI
10.1136/jitc-2021-002757
Rights and Permissions
Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, Lim AM, Hernandez-Aya L, Hughes BGM, Schadendorf D, Hauschild A, Thai AA, Stankevich E, Booth J, Yoo SY, Li S, Chen Z, Okoye E, Chen CI, Mastey V, Sasane M, Lowy I, Fury MG, Migden MR. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021 Aug;9(8):e002757. doi: 10.1136/jitc-2021-002757. https://jitc.bmj.com/content/9/8/e002757.long Copyright 2021 The Authors This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Recommended Citation
Rischin, Danny; Hernandez-Aya, Leonel; and et al, "Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: Extended follow-up of outcomes and quality of life analysis." Journal for Immunotherapy of Cancer. 9, 8. e002757 (2021).
https://digitalcommons.wustl.edu/oa_4/110
